Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inotiv, Inc. (NOTV : NSDQ)
 
 • Company Description   
Inotiv Inc. is a pharmaceutical development company. It involved in providing contract research services and monitoring instruments to emerging pharmaceutical companies. Inotiv Inc., formerly known as Bioanalytical Systems Inc., is based in WEST LAFAYETTE, Ind.

Number of Employees: 2,075

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.11 Daily Weekly Monthly
20 Day Moving Average: 465,598 shares
Shares Outstanding: 34.35 (millions)
Market Capitalization: $72.49 (millions)
Beta: 3.94
52 Week High: $6.48
52 Week Low: $1.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.21% -13.57%
12 Week 28.66% 8.22%
Year To Date -49.03% -52.27%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2701 KENT AVENUE
-
WEST LAFAYETTE,IN 47906
USA
ph: 765-463-4527
fax: 765-497-1102
dsullivan@equityny.com http://www.inotivco.com
 
 • General Corporate Information   
Officers
Robert W. Leasure, Jr. - President and Chief Executive Officer
R. Matthew Neff - Chairman
Beth A. Taylor - Chief Financial Officer and Senior Vice President
Brennan Freeman - Vice President of Finance and Corporate Controller
Nigel Brown - Director

Peer Information
Inotiv, Inc. (GSAC)
Inotiv, Inc. (CASI)
Inotiv, Inc. (ALCD.)
Inotiv, Inc. (OMNN)
Inotiv, Inc. (CGPI.)
Inotiv, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 45783Q100
SIC: 8731
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 34.35
Most Recent Split Date: (:1)
Beta: 3.94
Market Capitalization: $72.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.45
Price/Cash Flow: 1.37
Price / Sales: 0.15
EPS Growth
vs. Year Ago Period: 37.93%
vs. Previous Quarter: 57.14%
Sales Growth
vs. Year Ago Period: 4.44%
vs. Previous Quarter: 3.71%
ROE
06/30/25 - -
03/31/25 - -15.64
12/31/24 - -15.41
ROA
06/30/25 - -
03/31/25 - -3.44
12/31/24 - -3.58
Current Ratio
06/30/25 - -
03/31/25 - 1.50
12/31/24 - 1.57
Quick Ratio
06/30/25 - -
03/31/25 - 1.18
12/31/24 - 1.28
Operating Margin
06/30/25 - -
03/31/25 - -5.54
12/31/24 - -5.92
Net Margin
06/30/25 - -
03/31/25 - -18.21
12/31/24 - -25.40
Pre-Tax Margin
06/30/25 - -
03/31/25 - -21.39
12/31/24 - -29.73
Book Value
06/30/25 - -
03/31/25 - 4.68
12/31/24 - 5.04
Inventory Turnover
06/30/25 - -
03/31/25 - 11.87
12/31/24 - 11.13
Debt-to-Equity
06/30/25 - -
03/31/25 - 2.49
12/31/24 - 2.31
Debt-to-Capital
06/30/25 - -
03/31/25 - 71.33
12/31/24 - 69.82
 

Powered by Zacks Investment Research ©